2022 Regular Session • Maryland Legislature
SB353: Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act)
Legislative Summary
Requiring insurers, nonprofit health service plans, and health maintenance organizations to limit the amount a covered individual is required to pay in copayments or coinsurance for a covered prescription insulin drug to not more than $30 for a 30-day supply.
Bill History
1/21/2022
First Reading Finance
Senate
1/26/2022
Hearing 2/09 at 1:00 p.m.
Senate
3/7/2022
Favorable with Amendments Report by Finance
Senate
3/8/2022
Favorable with Amendments {173122/1 Adopted
Senate
3/8/2022
Second Reading Passed with Amendments
Senate
3/10/2022
Third Reading Passed (47-0)
Senate
3/11/2022
Referred Health and Government Operations
House of Delegates
3/18/2022
Hearing 3/24 at 1:30 p.m.
House of Delegates
3/30/2022
Favorable Report by Health and Government Operations
House of Delegates
3/30/2022
Favorable Adopted Second Reading Passed
House of Delegates
3/31/2022
Third Reading Passed (125-0)
House of Delegates
3/31/2022
Returned Passed
Senate
5/27/2022
Vetoed by the Governor (Duplicative)
Senate
Amendments
Favorable with Amendments 173122/1 Adopted
Favorable with Amendments 173122/1 Adopted
3/8/2022Adopted
Roll Call Votes
Third Reading Passed
3/31/2022
125
Yea
0
Nay
8
Not Voting
8
Absent
Result: PASSED
Third Reading Passed
3/10/2022
47
Yea
0
Nay
0
Not Voting
0
Absent
Result: PASSED
Status Information
Current Status
Vetoed(5/27/2022)
Chamber
Senate
Sine Die
Sponsors
Democrat: 14
Primary Sponsor
Clarence Lam
Democrat